2ⁿᵈ Edition of the Cancer R&D World Conference 2026
Scientific Sessions
Next Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Next-generation targeted therapies are redefining precision oncology by directly addressing key oncogenic drivers such as KRAS, HER2, BRAF, and NRAS. Once considered undruggable, these molecular targets are now at the forefront of therapeutic innovation, thanks to advances in structure-based drug design and molecular engineering. Breakthrough inhibitors and antibody–drug conjugates are demonstrating remarkable efficacy across multiple tumor types, offering new hope for patients with previously limited options. These targeted approaches not only enhance treatment precision but also minimize systemic toxicity and improve long-term outcomes.
This session will discuss the state-of-the-art developments in targeting KRAS, HER2, BRAF, and NRAS mutations at the Cancer Research and Development Conference 2026. Mechanisms of resistance, strategies for combination treatment, and incorporation into clinical decisions by molecular profiling will be addressed by the experts. Join us in finding out how these next-generation targeted therapies are bringing a sea change in cancer therapy to produce an unprecedented level of precision in treatment and personalized care.
Related Sessions
We, the Precision Global Conferences, welcome all the students, scholars, researchers, and delegates across the globe to patronize their presence at the ...
Read More>>
Organizer
